What are the specific effects and side effects of nintedanib/Vigat that you need to pay attention to?

Nintedanib (Nintedanib) is a multi-target tyrosine kinase inhibitor developed by Boehringer Ingelheim of Germany. It is internationally considered to be one of the important breakthrough drugs in the field of anti-fibrosis treatment. Its core mechanism of action is to simultaneously inhibit vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR), thereby blocking multiple signaling pathways related to tissue fibrosis and tumor angiogenesis. Through this mechanism, nintedanib can effectively inhibit the proliferation, migration and collagen deposition of abnormal fibroblasts, and fundamentally delay the progression of tissue fibrosis.

Nintedanib was initially approved for the treatment of idiopathic pulmonary fibrosis (IPF), and has since been gradually expanded to include systemic sclerosis-related interstitial lung disease (SSc-ILD) and chronic progressive interstitial lung disease (PF-ILD). For these diseases, traditional treatments have limited efficacy, and the emergence of nintedanib has significantly improved the course of patients' disease. Multiple overseas research results show that nintedanib can significantly reduce the rate of lung function decline, prolong progression-free survival, and improve patients' respiratory tolerance. Clinicians generally believe that although it cannot reverse the fibrosis that has already formed, it can effectively "suspend the course of the disease" and win more opportunities for treatment and recovery for patients. Some studies are also exploring its potential application in liver fibrosis and certain cancers, providing new ideas for future treatment directions.

However, as a targeted drug with a complex mechanism of action, nintedanib's side effects cannot be ignored. The most common side effect is digestive system reaction, in which the incidence of diarrhea is higher, and some patients may be accompanied by nausea, vomiting, bloating or loss of appetite. Clinically, it is recommended that patients take antidiarrheal drugs or adjust their diet under the guidance of a doctor to relieve gastrointestinal discomfort. If diarrhea is severe and persists, your doctor may recommend temporarily stopping the medication or lowering the dose. In addition, abnormal liver function is another type of adverse reaction that requires special attention. Some patients may experience elevated transaminases or bilirubin while taking nintedanib, so liver function tests should be performed regularly, especially in the first few months of treatment. For patients with chronic liver disease or impaired liver function, doctors will adjust the dosage or choose an alternative based on the specific situation.

Another issue to be aware of is the risk of bleeding. Because nintedanib mechanistically affects angiogenesis and platelet function, the risk should be carefully assessed in patients who are receiving anticoagulant therapy or who have had recent surgery. In addition, a small number of patients may experience systemic reactions such as increased blood pressure, weight loss, decreased appetite, and fatigue. Although most of these side effects are reversible, mild to moderate reactions, they still need to be monitored and dealt with under the guidance of a doctor. It is worth mentioning that female patients are not recommended to use nintedanib during pregnancy because animal experiments have shown that the drug may affect fetal development. Therefore, strict contraception is required and pregnancy should be planned for a certain period after stopping the drug.

From the perspective of drug characteristics, the toxic and side effects of nintedanib are mostly related to dosage and individual differences. Some patients interrupt treatment due to obvious adverse reactions in the early stages of use, but after dose adjustment and restarting the drug, good curative effects can often be achieved. Therefore, reasonable management of adverse reactions is a key link to ensure the efficacy of nintedanib.

Reference materials:https://en.wikipedia.org/wiki/Nintedanib